secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055286
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports 52% ORR in PDAC and 42% ORR in NSCLC for KRAS G12D inhibitor VS-7375
--------------------------------------------------------------------------------

- Phase 1 data from China: 23 PDAC patients had 52% ORR and 100% DCR; 12 NSCLC patients had 42% ORR and 83% DCR.
- No dose-limiting toxicities observed across 100-900 mg QD; TRAEs mostly Grade 1/2; no TRAE-related deaths.
- U.S. Phase 1/2a study for VS-7375 to start at 400 mg dose; plans to evaluate monotherapy and combinations in pancreatic, colorectal, and NSCLC.
- Data presented at ASCO 2025; GenFleet is partner in China; Verastem holds rights in U.S. and other regions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/0001104659-25-055286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/tm2516844d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer